Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies

Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies

<p dir="ltr">Small molecule therapy is a critical component of targeted anticancer treatment, with tyrosine kinase inhibitors (TKIs) being the first compounds to treat the clonal Chronic Myelogenous Leukaemia (CML) translocation t (9;22) (q34; q11) effectively since 2001. TKIs, such...

Full description

Saved in:
Bibliographic Details
Main Author: Salma Younes (6424865) (author)
Other Authors: Mohamed A. Ismail (418629) (author), Rana Al-Jurf (14150016) (author), Ayah Ziyada (17931443) (author), Gheyath K. Nasrallah (9200525) (author), Palli Valapila Abdulrouf (11619462) (author), Mohamed Nagy (11874959) (author), Hatem Zayed (835448) (author), Thomas Farrell (3933833) (author), Claudio Sorio (212799) (author), Hisham Morsi (14152881) (author), M. Walid Qoronfleh (14153088) (author), Nader I. Al-Dewik (14152884) (author)
Published: 2023
Subjects:
Biological sciences
Biochemistry and cell biology
Biomedical and clinical sciences
Cardiovascular medicine and haematology
Clinical sciences
Oncology and carcinogenesis
Pharmacology and pharmaceutical sciences
Tyrosine kinase inhibitors (TKIs)
BCR::ABL1;
Chronic Myeloid Leukaemia (CML)
resistance
therapeutic targets
cancer
personalized medicine
precision medicine
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items